Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Xaluritamig by Amgen for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Xaluritamig is under clinical development by Amgen and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Data Insights
Xaluritamig by Amgen for Prostate Cancer: Likelihood of Approval
Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I...